AdMSC

Phase 2Small molecule

UUniversity Hospital, Toulouse

AdMSC is one of 41 small molecule programs targeting Early Alzheimer's Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Early Alzheimer's DiseaseRecruiting

Crohn's FistulaRecruiting

SclerodermaRecruiting

Systemic SclerodermaNot yet recruiting

Early Alzheimer's DiseasePhase 2

Recruiting

Crohn's FistulaPhase 2

Recruiting

SclerodermaPhase 2

Recruiting

Systemic SclerodermaPhase 2

Not yet recruiting

Competition

Competitive Landscape

22 competitors in Systemic Scleroderma

#DrugCompanyPhaseTrials

Adempas

Buspar

Tracleer

Cellcept

Remodulin

Crestor

Gleevec

Cialis

Medrol

Thalomid

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1/2Recruiting

Early Alzheimer's Disease

NCT06775964

Phase 2Recruiting

Scleroderma

NCT04356755

Q3 2027

Phase 1/2Recruiting

Crohn's Fistula

NCT06636032

Q3 2028

Phase 2Not yet recruiting

Systemic Scleroderma

NCT07326033

Clinical

Trials by Indication[1]

Systemic Scleroderma1 trial

Efficacy and Safety of Allogenic Cultured Adipose-derived Mesenchymal Stromal Cell Injections on MoUth Fibrosis and Handicap in Patients With Systemic sclEroderma

Not yet recruiting·UUniversity Hospital, Toulouse·Phase 2·NCT07326033·50 enrolled

Early Alzheimer's Disease1 trial

Stem Cell Therapy for Early Alzheimer's Disease

Recruiting·PPaul E Schulz·Phase 1/2·NCT06775964·12 enrolled

Scleroderma1 trial

Subcutaneous Injections of ASC to Heal Digital Ulcers in Patients With Scleroderma.

Recruiting·UUniversity Hospital, Toulouse·Phase 2·NCT04356755·32 enrolled

Crohn's Fistula1 trial

Dose Escalation of Allogeneic Adipose Derived Stroma/Stem Cells for the Treatment of Crohn's Fistula

Recruiting·UUniversity Hospital, Toulouse·Phase 1/2·NCT06636032·9 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for AdMSC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — AdMSC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for AdMSC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Hospital, Toulouse company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity Hospital, Toulouse

AdMSC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q3 2027

Q3 2028

Trials by Indication[1]

Systemic Scleroderma1 trial

Early Alzheimer's Disease1 trial

Scleroderma1 trial

Crohn's Fistula1 trial

References

Drug Info

Quick Facts

Related News